Prognostic PCR assay for severe acute respiratory syndrome (SARS)
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
May 26, 2005
app pub date -
Sep 23, 2004
filing date -
Sep 24, 2003
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
Disclosed are nucleic acid primers, probes and standard target sequences that allow for the quantitative assessment of the SARS-CoV viral titer found in a biological specimen from a patient. Quantifying the viral titer in the patient sample allows the practitioner to make a prognostic determination of the severity of the SARS-CoV infection and the necessary treatment regime.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully